论文部分内容阅读
目的:探讨艾替伏辛（Etifoxine）对大鼠许旺细胞（RSC96）增殖和迁移的影响及分子机制。方法:2020年3月-2020年10月,观察Etifoxine对RSC96 SCs增殖和迁移的影响,将细胞分为20 μmol/L Etifoxine组和生理盐水组,处理48 h后使用EDU细胞增殖检测试剂盒、Transwell实验以及划痕实验检测细胞增殖和迁移能力的变化。观察Etifoxine对RSC96、表皮生长因子样蛋白2抗原（CELSR2）蛋白表达的影响,建立Etifoxine浓度梯度,将细胞分别用生理盐水组和5 μmol/L、10 μmol/L和20 μmol/L Etifoxine进行培养,48 h后通过Western blot检测各组细胞CELSR2蛋白表达。探讨CELSR2是否为Etifoxine的潜在作用靶点,将细胞分为20 μmol/L Etifoxine加CELSR2 siRNA组和20 μmol/L Etifoxine加Control siRNA组,处理48 h后再次检测细胞增殖和迁移情况。采用非参数Mann-Whitney检验进行数据分析,n P<0.05表示差异有统计学意义。n 结果:EdU和Transwell实验结果显示,20 μmol/L Etifoxine处理组RSC96细胞增殖率（36.30±3.09）%、迁移细胞数量（132.30±6.77）均高于对照组[分别为（19.40±2.50）%和65.33±7.37],24 h和36 h划痕愈合率分别为（30.67±2.16）%和（86.00±2.19）%,均高于对照组[分别为（23.00±2.61）%和（49.67±2.81）%],差异有统计学意义（n P<0.05）。Western blot结果显示,随着Etifoxine浓度升高,RSC96细胞CELSR2蛋白表达增多（n P0.05）。经20 μmol/L Etifoxine处理的RSC96细胞转染CELSR2 siRNA后,与对照组相比,细胞增殖率、迁移细胞数量以及24 h/36 h划痕愈合率均明显下降（n P<0.05）。n 结论:Etifoxine可促进RSC96增殖及迁移,而且Etifoxine诱导的增殖和迁移促进作用与RSC96 CELSR2蛋白表达上调相关。“,”Objective:To observe the effects of Etifoxine on proliferation and migration of RSC96 (Schwann cells of rat) and its potential molecular mechanisms.Methods:From March, 2020 to October, 2020, cultured RSC96 were treated with 20 μmol/L Etifoxine and saline respectively for 48 h. Cell proliferation was tested by EdU assay using Cell-Light EdU DNA Cell Proliferation Kit and the capability of migration was determined by wound healing assay and a transwell system. To investigate the effects of Etifoxine on CELSR2 protein expression, after treated with different concentrations of Etifoxine at 0-20 μmol/L for 48 hours, cells were subject to Western blot analysis to verify the expression of CELSR2 protein. To explore whether CELSR2 would be a potential target of Etifoxine, siRNA targeting CELSR2 and control siRNA groups were transfected into 20 μmol/L Etifoxine-treated RSC96 using Lipo3000. Again, the cell proliferation and migration of were investigated after 48 hours with the same procedures. The two-tailed Mann-Whitney U test was employed in statistical assessment.Results:EdU results showed a significant higher percentage of Edu-positive (proliferating) cells in the 20 μmol/L Etifoxine-treated group than the control group[(36.30±3.09)% n vs (19.40±2.50)%, n P<0.05]. Transwell migration assay demonstrated that the number of 20 μmol/L Etifoxine-treated RSC96 which migrated through the transwell membrane was higher than saline group, with significant statistical difference [(132.30±6.77)n vs(65.33±7.37), n P<0.05]. The percentage of reduction of wound area measured at 24 hours and 36 hours after the scratch also showed the similar results [(30.67±2.16)%n vs (23.00±2.61)%; (86.00±2.19)% n vs (49.67±2.81)%, respectively, n P<0.05]. Besides, with increase of the concentration of etifoxine, the expression of CELSR2 showed an trend of increase in RSC96 (n P0.05). Interestingly, the rate of cell proliferation, the number of migrating cells and the percentage of wound area reduction of RSC96 in which were treated by Etifoxine and transfected with CELSR2 siRNA were significantly decreased compared with the control siRNA treatment (n P<0.05).n Conclusion:Etifoxine could promote proliferation and migration of RSC96. Upregulation of CELSR2 protein expression in RSC96 is associated with the Etifoxine-induced enhancement of cell proliferation and migration.